PGD

CancerPRO™ Plasma
Coming Soon

Identify relevant somatic alterations in cancer without invasive biopsies

CancerPRO™ Plasma is a pre-designed targeted gene panel for use with the PRO**GENE**US™ platform, that analyzes the regions of 10 well-characterized cancer genes using proprietary laboratory and bioinformatics methods.

CancerPRO P10 Test Highlights

- Identifies sequence mutations, indels, amplifications and genomic rearrangements
- Able to detect sequence mutations and translocations down to 0.1% ctDNA levels with high specificity
- Tests for all alterations in the NCCN non-small lung cancer test guidelines

CancerPRO P10 Genes Evaluated		
Sequence Mutations	**Translocations**	**Amplifications**
Gene	**Gene**	**Gene**
BRAF	ALK	ERBB2
EGFR	EGFR	MET
ERBB2	NTRK1	
KRAS	RET	
MET	ROS1	
NRAS		

Benefits of Using Plasma for Cancer Mutation Analyses

The majority of advanced disease samples will have mutations found at low circulating tumor DNA levels and detectable by CancerPRO P10 including most non-small cell lung cancer cases.

A Non-invasive, Liquid Biopsy Assay will be Helpful When:

- A biopsy is not available or is insufficient
- Biopsy DNA is of poor quality
- The tumor may have acquired mutations as a result of treatments since the original biopsy was taken
- There is a need to detect genetic alterations in multiple lesions simultaneously
- There is a need to track mutation status over multiple time points

CancerPRO Plasma Sample & Sequencing Requirements	
Regions Analyzed	Selected regions of 10 genes
Sequencing Method	Illumina next generation sequencing
Bioinformatics	Patented PARE, Digital Karyotyping, and proprietary error-correction methods
Assay Limit of Detection	0.10% Mutant Allele Fraction (MAF)
Assay Specificity (PPV)	>99%
Target Sequencing Coverage (recommended)	30,000x for sequence mutations; 5,000x for structural alterations
Turnaround Time	1 week
Sample Requirements	10 ng DNA (1 ml of plasma)
Sample Types	Whole Blood or Plasma, EDTA or Streck tubes

INNOVATIVE GENOMIC TECHNOLOGIES TO SOLVE FUNDAMENTAL CHALLENGES IN ONCOLOGY
LEARN MORE AT PERSONALGENOME.COM/PRO**GENE**US OR CALL FOR A QUOTE 443-408-8071

PERSONAL GENOME DIAGNOSTICS | 2809 BOSTON STREET, SUITE 503 | BALTIMORE, MARYLAND 21224 | TEL 443-408-8071

12/2015 ES-004-V2